Argenx demonstrates commitment to redefining treatment goals for generalized myasthenia gravis with multiple presentations at american academy of neurology 2023 annual meeting

Amsterdam, the netherlands – [0 4 / 18 /2023] argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will present six abstracts further demonstrating its long-term commitment to the generalized myasthenia gravis (gmg) community during the 75th american academy of neurology (aan) annual meeting, which is taking place from april 22-27, 2023 in boston, ma. the presentations include clinical and real-world efgartigimod data that demonstrate the potential of neonatal fc receptor (fcrn) blockade in transforming treatment for gmg and other igg-mediated autoimmune diseases.
ARGX Ratings Summary
ARGX Quant Ranking